drugset
Drugs / MVA-SARS-2-S
last change Nov 2022 re-read 2 minutes ago

MVA-SARS-2-S

Vaccine

Developed for
COVID-19
Investigated by
German Center for Infection Research · Ludwig-Maximilians - University of Munich · Philipps University Marburg · University Medical Center Hamburg-Eppendorf · CTC-NORTH · University Hospital Tuebingen

Trials 2 · a red edge is where a trial was stopped

today NCT05950776 · Ph 2 NCT04569383 · Ph 1
202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT04569383 Oct 2020 → Aug 2021 COVID-19 University Medical Center Hamburg-Eppendorf Completed No outcome recorded
Phase 21 trial
Phase 2 NCT05950776 Jan 2021 → Nov 2022 COVID-19 University Medical Center Hamburg-Eppendorf Withdrawn No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as MVA-SARS-2-S ClinicalTrials.gov intervention name — accepted as the source's own label NCT05950776 ↗
1

NCT04569383 ↗
Modality Vaccine “Vaccination with MVA-SARS-2-S in two escalating dose regimens” NCT04569383 ↗